Insider · CIK 0001417397
Steven L Basta
Files at YARW (VYNE Therapeutics Inc.), PHAT (Phathom Pharmaceuticals, Inc.). First filing -, latest -.
Steven L Basta files SEC Form 4 as director, CEO and president at YARW (VYNE Therapeutics Inc.), and also at PHAT (Phathom Pharmaceuticals, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Steven L Basta has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 10, 2026 | PHAT Phathom Pharmaceuticals, Inc. | AGrant or award Common Stock | +12,362 | $0.00 | $0 | 379,592 | Feb 12, 2026 |
| Feb 10, 2026 | PHAT Phathom Pharmaceuticals, Inc. | FTax withholding Common Stock | -6,277 | $12.82 | $80k | 373,315 | Feb 12, 2026 |
| Jan 2, 2026 | PHAT Phathom Pharmaceuticals, Inc. | AGrant or award Common Stock | +251,034 | $0.00 | $0 | 364,820 | Jan 2, 2026 |
| Jan 2, 2026 | PHAT Phathom Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +226,156 | $0.00 | $0 | 221,156 | Jan 2, 2026 |
| Dec 17, 2025 | PHAT Phathom Pharmaceuticals, Inc. | AGrant or award Common Stock | +62,038 | $0.00 | $0 | 145,288 | Dec 19, 2025 |
| Dec 17, 2025 | PHAT Phathom Pharmaceuticals, Inc. | FTax withholding Common Stock | -31,502 | $15.36 | $484k | 113,786 | Dec 19, 2025 |
| Dec 12, 2025 | YARW VYNE Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Dec 15, 2025 |
| Nov 28, 2025 | PHAT Phathom Pharmaceuticals, Inc. | MOption exercise Common Stock | +90,000 | $0.00 | $0 | 131,625 | Dec 2, 2025 |
| Nov 28, 2025 | PHAT Phathom Pharmaceuticals, Inc. | FTax withholding Common Stock | -48,375 | $15.62 | $756k | 83,250 | Dec 2, 2025 |
| Nov 28, 2025 | PHAT Phathom Pharmaceuticals, Inc. | MOption exercise Performance Sharesderivative | -90,000 | $0.00 | $0 | 180,000 | Dec 2, 2025 |
| Sep 25, 2025 | PHAT Phathom Pharmaceuticals, Inc. | MOption exercise Common Stock | +90,000 | $0.00 | $0 | 90,000 | Sep 26, 2025 |
| Sep 25, 2025 | PHAT Phathom Pharmaceuticals, Inc. | FTax withholding Common Stock | -48,375 | $11.66 | $564k | 41,625 | Sep 26, 2025 |
| Sep 25, 2025 | PHAT Phathom Pharmaceuticals, Inc. | MOption exercise Performance Sharesderivative | -90,000 | $0.00 | $0 | 270,000 | Sep 26, 2025 |
| Apr 3, 2025 | PHAT Phathom Pharmaceuticals, Inc. | AGrant or award Performance Sharesderivative | +360,000 | $0.00 | $0 | 360,000 | Apr 3, 2025 |
| Apr 3, 2025 | PHAT Phathom Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,085,000 | $0.00 | $0 | 1,085,000 | Apr 3, 2025 |
| Dec 12, 2024 | YARW VYNE Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Dec 13, 2024 |
Questions about Steven L Basta
Answered from the filings on this page, as of the latest one.
Is Steven L Basta buying or selling?
Steven L Basta has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Steven L Basta's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Steven L Basta has 0.
Where does Steven L Basta file Form 4?
Steven L Basta has filed Form 4 at YARW (VYNE Therapeutics Inc.); PHAT (Phathom Pharmaceuticals, Inc.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.